Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
AssigneeSage Therapeutics, Inc.
InventorsPaul Steven Watson, Bret Berner, John Gregory Reid, Jian Wang, James J. Doherty, Stephen Jay Kanes
Life of this patent
Estimating the term…
Abstract
This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.
Claims5
A crystalline solid form of Compound 1:
- having an XRPD pattern comprising peaks between and including 9.7 to 10.1 degrees in 2θ, between and including 11.6 to 12.0 degrees in 2θ, between and including 13.2 to 13.6 degrees in 2θ, between and including 14.2 to 14.6 degrees in 2θ, between and including 14.6 to 15.0 degrees in 2θ, between and including 16.8 to 17.2 degrees in 2θ, between and including 20.5 to 20.9 degrees in 2θ, between and including 21.3 to 21.7 degrees in 2θ, between and including 21.4 to 21.8 degrees in 2θ, and between and including 22.4 to 22.8 degrees in 2θ.
A crystalline solid form of Compound 1:
- having an XRPD pattern comprising peaks between and including 9.7 to 10.1 degrees in 2θ, between and including 14.6 to 15.0 degrees in 2θ, between and including 16.8 to 17.2 degrees in 2θ, between and including 20.5 to 20.9 degrees in 2θ, between and including 21.3 to 21.7 degrees in 2θ.
The A crystalline solid form of Compound 1:
- having an XRPD pattern comprising peaks at 9.9 degrees in 2θ, 14.8 degrees in 2θ, 17.0 degrees in 2θ, 20.7 degrees in 2θ, and 21.5 degrees in 2θ.
Dependencies are inferred from the claim text.